ReviewApplied health economics and health policy2026
Speed over Value: Korea's Recent Overhaul in Pharmaceutical Pricing and Reimbursement.
Review in Applied health economics and health policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 2007, South Korea has been a leading country in Asia in health technology assessment (HTA). In March 2026, a 100-day listing pathway using international reference pricing (IRP) without pre-reimbursement HTA was introduced for rare disease drugs, with plans to expand to all new drugs. This policy represents a fundamental shift from ex-ante to ex-post value assessment, de-prioritizing the cost-effectiveness analysis framework established in 2007. Given the lessons from IRP, the global movement toward value-based pricing, and Korea's current financial challenges, it is essential to develop a system that leverages the accumulated knowledge on HTA over the past two decades to balance expedited access with rigorous value assessment. Therefore, further specified post-evaluation mechanisms incorporating value for money principles are needed to avoid undermining value assessment and diverging from the global trend toward strengthening value-based healthcare.
Identifiers
42828617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.